What is BPS Bioscience?
BPS Bioscience is a key provider of innovative tools and solutions essential for drug discovery, with a strategic focus on critical areas such as immunotherapy, CAR T-cell therapy, and epigenetics. The company's comprehensive product portfolio encompasses proteins, biochemical assay kits, cell lines, and virus-based tools, serving a broad spectrum of life science researchers. Beyond its product offerings, BPS Bioscience extends its expertise through custom development services and compound screening, actively supporting the progression of therapeutic research and development. Their dedication to maintaining high standards of quality and customer satisfaction aims to accelerate scientific breakthroughs in medicine.
How much funding has BPS Bioscience raised?
BPS Bioscience has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in BPS Bioscience
PPP
Public-Private Partnership
What's next for BPS Bioscience?
The substantial late-stage funding context suggests BPS Bioscience is poised for significant scaling and expansion. This capital infusion is likely to accelerate the development and commercialization of their advanced tools for immunotherapy and epigenetics research. Future strategic moves may involve expanding their product lines, forging new partnerships within the pharmaceutical and biotechnology industries, and potentially increasing their global market reach to support a wider array of drug discovery initiatives. The company's focus on cutting-edge therapeutic areas indicates a strong trajectory towards becoming a more dominant player in the life sciences innovation ecosystem.
See full BPS Bioscience company page
